Cargando…

Ceftriaxone-Associated Severe Acute Hepatitis

Drug-induced liver injury (DILI) is a common entity. Ceftriaxone is a well-tolerated parenteral antibiotic widely used for various bacterial infections. We report a patient who developed severe acute hepatitis following a single dose of 2 g ceftriaxone within one day. Apart from a fever of 101.9 F,...

Descripción completa

Detalles Bibliográficos
Autores principales: Asif, Muhammad, Khan, Wahab J, Aslam, Sadia, Nadeem, Ifrah, Singal, Ashwani K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110998/
https://www.ncbi.nlm.nih.gov/pubmed/37082506
http://dx.doi.org/10.7759/cureus.36341
_version_ 1785027368577925120
author Asif, Muhammad
Khan, Wahab J
Aslam, Sadia
Nadeem, Ifrah
Singal, Ashwani K
author_facet Asif, Muhammad
Khan, Wahab J
Aslam, Sadia
Nadeem, Ifrah
Singal, Ashwani K
author_sort Asif, Muhammad
collection PubMed
description Drug-induced liver injury (DILI) is a common entity. Ceftriaxone is a well-tolerated parenteral antibiotic widely used for various bacterial infections. We report a patient who developed severe acute hepatitis following a single dose of 2 g ceftriaxone within one day. Apart from a fever of 101.9 F, no other insult was noted to explain his severe hepatocellular injury around the time of presentation. On stopping further ceftriaxone, his symptoms resolved, and liver enzymes normalized within a week. His Roussel Uclaf Causality Assessment Method (RUCAM) score was 6 which suggested DILI be a probable cause of his acute hepatitis. Further surveillance at a larger scale is needed to support evidence for this rare side effect.
format Online
Article
Text
id pubmed-10110998
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-101109982023-04-19 Ceftriaxone-Associated Severe Acute Hepatitis Asif, Muhammad Khan, Wahab J Aslam, Sadia Nadeem, Ifrah Singal, Ashwani K Cureus Internal Medicine Drug-induced liver injury (DILI) is a common entity. Ceftriaxone is a well-tolerated parenteral antibiotic widely used for various bacterial infections. We report a patient who developed severe acute hepatitis following a single dose of 2 g ceftriaxone within one day. Apart from a fever of 101.9 F, no other insult was noted to explain his severe hepatocellular injury around the time of presentation. On stopping further ceftriaxone, his symptoms resolved, and liver enzymes normalized within a week. His Roussel Uclaf Causality Assessment Method (RUCAM) score was 6 which suggested DILI be a probable cause of his acute hepatitis. Further surveillance at a larger scale is needed to support evidence for this rare side effect. Cureus 2023-03-18 /pmc/articles/PMC10110998/ /pubmed/37082506 http://dx.doi.org/10.7759/cureus.36341 Text en Copyright © 2023, Asif et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Asif, Muhammad
Khan, Wahab J
Aslam, Sadia
Nadeem, Ifrah
Singal, Ashwani K
Ceftriaxone-Associated Severe Acute Hepatitis
title Ceftriaxone-Associated Severe Acute Hepatitis
title_full Ceftriaxone-Associated Severe Acute Hepatitis
title_fullStr Ceftriaxone-Associated Severe Acute Hepatitis
title_full_unstemmed Ceftriaxone-Associated Severe Acute Hepatitis
title_short Ceftriaxone-Associated Severe Acute Hepatitis
title_sort ceftriaxone-associated severe acute hepatitis
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110998/
https://www.ncbi.nlm.nih.gov/pubmed/37082506
http://dx.doi.org/10.7759/cureus.36341
work_keys_str_mv AT asifmuhammad ceftriaxoneassociatedsevereacutehepatitis
AT khanwahabj ceftriaxoneassociatedsevereacutehepatitis
AT aslamsadia ceftriaxoneassociatedsevereacutehepatitis
AT nadeemifrah ceftriaxoneassociatedsevereacutehepatitis
AT singalashwanik ceftriaxoneassociatedsevereacutehepatitis